Pharmaceutical composition for immunisation against aids
AssigneeNone recorded
InventorsFrancois Dalenccon, Jean Haensler
Life of this patent
Estimating the term…
Loading patent…
AssigneeNone recorded
InventorsFrancois Dalenccon, Jean Haensler
Estimating the term…
The invention relates to the field of pharmaceutical compositions for use in immunisation against HIV-related infections, and concerns a pharmaceutical composition comprising at least a HIV antigen and DCchol. Such a composition has proved to be particularly interesting for inducing through the mucous system IgG and IgA specific to the administered antigen. The inventive pharmaceutical composition, in a particular advantageous manner, can be in the form of liposome suspension, or emulsion.
A pharmaceutical composition, characterized in that it comprises at least one HIV antigen and DCchol.
The pharmaceutical composition as claimed in one of the preceding claims, characterized in that the DCchol is present in the form of a liposomal suspension.
The pharmaceutical composition as claimed in one of the preceding claims, characterized in that the DCchol is present in the form of an emulsion.
The use of a composition comprising at least one HIV antigen and DCchol, for producing a medicinal product for immunization against HIV-related infections.
The use as claimed in the preceding claim, characterized in that the immunization is carried out mucosally.
A method of immunizing a mammal against HIV, according to which at least one HIV antigen and also DCchol are administered to said mammal.
A method of inducing, in the mucosal tissues of a mammal, IgG or IgA antibodies specific for an HIV antigen, according to which a pharmaceutical composition comprising at least one HIV antigen and DCchol is administered to said mammal.
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
No related US applications are recorded in the indexed filing history.
Backward citations are indexed for grants only.
Viral antigens: retroviridae, e.g. equine infectious anemia virus
Medicinal preparations containing antigens or antibodies: viral antigens
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Term end not estimated
The present invention relates to the field of pharmaceutical compositions for use in immunization against HIV-related infections.
Acquired immunodeficiency syndrome, or AIDS, is a disease against which it would be highly desirable to be able to have a vaccine, and in particular a vaccine for use in prophylaxis. Now, until today, the development of such a vaccine has come up against many problems, including in particular the diverse forms which the HIV virus can take, also the difficulties in identifying the correlates of immunity against HIV, i.e. the immune factors capable of protecting against viruses. Cases of individuals who have been exposed and not infected, and also studies on “non-progressors” give indications, however, and direct research toward the induction of 2 types of immune response: the response by antibodies (humoral response) and the cellular response.
The humoral response that it is desirable to provoke is not only a systemic humoral response, but also a mucosal response since it is desirable to be able to put up an immune barrier against the virus at the site of its entry into the organism.
DC-Chol hydrochloride was used (obtained according to the method of preparation described in Example 8 of patent application WO 96/40067), which was suspended at 20 mg/ml in TRIS-NaCl buffer (20 mM TRIS, 150 mM NaCl, pH 6.8). After 8 hours with stirring at 35-40° C. under argon, the suspension was microfluidized using an M-110S microfluidizer from Microfluidics (10 cycles at 500 kPa), in order to generate a homogeneous suspension of DC-Chol, which was filtered through a 0.45 μm Millex filter.
Oligonucleotides were prepared using an automatic synthesizer provided by Applied Biosystems, which uses the standard phosphoramidite chemical method and which comprises an oxidation step at each cycle.
This oxidation step was carried out using an iodine/water/tetrahydrofuran/acetonitrile solution so as to obtain a phosphodiester bond, and using a tetraethylthiuram/acetonitrile solution so as to obtain a phosphorothioate bond.